These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 29370450)
1. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450 [TBL] [Abstract][Full Text] [Related]
2. Usefulness of Yokose T; Kitago M; Matsusaka Y; Masugi Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Endo Y; Toyama K; Iwabuchi Y; Takemura R; Ishii R; Nakahara T; Okuda S; Jinzaki M; Kitagawa Y Cancer Med; 2020 Jun; 9(12):4059-4068. PubMed ID: 32281301 [TBL] [Abstract][Full Text] [Related]
3. Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. Cloyd JM; Crane CH; Koay EJ; Das P; Krishnan S; Prakash L; Snyder RA; Varadhachary GR; Wolff RA; Javle M; Shroff RT; Fogelman D; Overman M; Wang H; Maitra A; Lee JE; Fleming JB; Katz MH Cancer; 2016 Sep; 122(17):2671-9. PubMed ID: 27243381 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11). Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040 [TBL] [Abstract][Full Text] [Related]
5. Assessment of Response to Neoadjuvant Therapy Using CT Texture Analysis in Patients With Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Borhani AA; Dewan R; Furlan A; Seiser N; Zureikat AH; Singhi AD; Boone B; Bahary N; Hogg ME; Lotze M; Zeh HJ; Tublin ME AJR Am J Roentgenol; 2020 Feb; 214(2):362-369. PubMed ID: 31799875 [No Abstract] [Full Text] [Related]
6. Borderline Resectable and Locally Advanced Pancreatic Cancer: FDG PET/MRI and CT Tumor Metrics for Assessment of Pathologic Response to Neoadjuvant Therapy and Prediction of Survival. Panda A; Garg I; Truty MJ; Kline TL; Johnson MP; Ehman EC; Suman G; Anaam DA; Kemp BJ; Johnson GB; Halfdanarson TR; Venkatesh SK; Fidler JL; Goenka AH AJR Am J Roentgenol; 2021 Sep; 217(3):730-740. PubMed ID: 33084382 [No Abstract] [Full Text] [Related]
7. Perfusion CT to Assess Response to Neoadjuvant Chemotherapy and Radiation Therapy in Pancreatic Ductal Adenocarcinoma: Initial Experience. Hamdy A; Ichikawa Y; Toyomasu Y; Nagata M; Nagasawa N; Nomoto Y; Sami H; Sakuma H Radiology; 2019 Sep; 292(3):628-635. PubMed ID: 31287389 [TBL] [Abstract][Full Text] [Related]
8. Nodal downstaging as a treatment goal for node-positive pancreatic cancer. Portuondo JI; Massarweh NN; Zhang Q; Chai CY; Tran Cao HS Surgery; 2019 Jun; 165(6):1144-1150. PubMed ID: 30745009 [TBL] [Abstract][Full Text] [Related]
9. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes. Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284 [TBL] [Abstract][Full Text] [Related]
10. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? He J; Blair AB; Groot VP; Javed AA; Burkhart RA; Gemenetzis G; Hruban RH; Waters KM; Poling J; Zheng L; Laheru D; Herman JM; Makary MA; Weiss MJ; Cameron JL; Wolfgang CL Ann Surg; 2018 Jul; 268(1):1-8. PubMed ID: 29334562 [TBL] [Abstract][Full Text] [Related]
11. Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. Perri G; Prakash L; Wang H; Bhosale P; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay E; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG Ann Surg; 2021 Apr; 273(4):806-813. PubMed ID: 31274655 [TBL] [Abstract][Full Text] [Related]
12. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection. Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211 [TBL] [Abstract][Full Text] [Related]
13. Carbohydrate Antigen 19-9 Elevation in Anatomically Resectable, Early Stage Pancreatic Cancer Is Independently Associated with Decreased Overall Survival and an Indication for Neoadjuvant Therapy: A National Cancer Database Study. Bergquist JR; Puig CA; Shubert CR; Groeschl RT; Habermann EB; Kendrick ML; Nagorney DM; Smoot RL; Farnell MB; Truty MJ J Am Coll Surg; 2016 Jul; 223(1):52-65. PubMed ID: 27049786 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathological correlation of radiologic measurement of post-therapy tumor size and tumor volume for pancreatic ductal adenocarcinoma. Wei D; Zaid MM; Katz MH; Prakash LR; Kim M; Tzeng CD; Lee JE; Agrawal A; Rashid A; Wang H; Varadhachary G; Wolff RA; Tamm EP; Bhosale PR; Maitra A; Koay EJ; Wang H Pancreatology; 2021 Jan; 21(1):200-207. PubMed ID: 33221151 [TBL] [Abstract][Full Text] [Related]
15. Clinical benefits of neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreatic head: an observational study using inverse probability of treatment weighting. Fujii T; Satoi S; Yamada S; Murotani K; Yanagimoto H; Takami H; Yamamoto T; Kanda M; Yamaki S; Hirooka S; Kon M; Kodera Y J Gastroenterol; 2017 Jan; 52(1):81-93. PubMed ID: 27169844 [TBL] [Abstract][Full Text] [Related]
16. Pancreatic ductal adenocarcinoma: tumour regression grading following neoadjuvant FOLFIRINOX and radiation. Neyaz A; Tabb ES; Shih A; Zhao Q; Shroff S; Taylor MS; Rickelt S; Wo JY; Fernandez-Del Castillo C; Qadan M; Hong TS; Lillemoe KD; Ting DT; Ferrone CR; Deshpande V Histopathology; 2020 Jul; 77(1):35-45. PubMed ID: 32031712 [TBL] [Abstract][Full Text] [Related]
17. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998 [TBL] [Abstract][Full Text] [Related]
18. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma. Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723 [TBL] [Abstract][Full Text] [Related]
19. Alteration of strain ratio evaluated by transabdominal ultrasound elastography may predict the efficacy of preoperative chemoradiation performed for pancreatic ductal carcinoma: preliminary results. Kawada N; Tanaka S; Uehara H; Katayama K; Hosoki T; Takami M; Tomita Y Hepatogastroenterology; 2014; 61(130):480-3. PubMed ID: 24901166 [TBL] [Abstract][Full Text] [Related]
20. Perspectives in the treatment of pancreatic adenocarcinoma. Cid-Arregui A; Juarez V World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]